evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

57 questions · 65 findings · 14 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 8 · 12.3%GRADE not reported 5 · 7.7%Very low 15 · 23.1%Low 20 · 30.8%Moderate 10 · 15.4%High 7 · 10.8%

Low molecular weight heparin vs vitamin K antagonist (VKA)

Symptomatic catheter‐related thrombosis measured as asymptomatic catheter‐related thrombosis (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters

It is very uncertain whether low‐molecular‐weight heparin (LMWH) changes symptomatic catheter‐related thrombosis measured as asymptomatic… compared with vitamin K antagonist (VKA) (very low certainty).

1 finding from 1 review

Low molecular weight heparin vs no LMWH

Symptomatic catheter‐related thrombosis measured as asymptomatic catheter‐related thrombosis (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters

It is very uncertain whether low‐molecular‐weight heparin (LMWH) changes symptomatic catheter‐related thrombosis measured as asymptomatic… compared with no LMWH (very low certainty).

1 finding from 1 review

Peripartum/postnatal prophylaxis (caesarean): heparin (LMWH or UFH) vs no treatment/placebo

Symptomatic PE · women giving birth by elective or emergency caesarean (elective only (1 trial), emergency or elective (4 trials))

It is very uncertain whether peripartum/postnatal prophylaxis (caesarean): heparin (LMWH or UFH) changes symptomatic PE (timing of assessment unclear, within 6 weeks… compared with no treatment/placebo (very low certainty).

1 finding from 1 review

Peripartum/postnatal prophylaxis (caesarean): heparin (LMWH or UFH) vs no treatment/placebo

Symptomatic thromboembolic events ( · women giving birth by elective or emergency caesarean (elective only (1 trial), emergency or elective (4 trials))

It is very uncertain whether peripartum/postnatal prophylaxis (caesarean): heparin (LMWH or UFH) changes symptomatic thromboembolic events (timing of assessment unclear,… compared with no treatment/placebo (very low certainty).

1 finding from 1 review

Aspirin vs low molecular weight heparin

Symptomatic DVT · ambulatory patients with multiple myeloma receiving immunomodulatory agents

It is very uncertain whether aspirin (ASA) changes symptomatic deep vein thrombosis compared with low molecular weight heparin (LMWH) (very low certainty).

2 findings from 1 review

Vitamin K antagonists vs low molecular weight heparin

Symptomatic DVT · ambulatory patients with multiple myeloma receiving immunomodulatory agents

It is very uncertain whether vitamin K antagonist (VKA) changes symptomatic deep vein thrombosis compared with low molecular weight heparin (LMWH) (very low certainty).

2 findings from 1 review

Vitamin K antagonists vs heparin

Symptomatic PE Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Vitamin K antagonists showed no clear difference in symptomatic PE Treatment duration 28 ‐ 42 days compared with heparin (low certainty).

1 finding from 1 review

DOAC vs heparin

Symptomatic PE Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

DOAC showed no clear difference in symptomatic PE Treatment duration 28 ‐ 42 days compared with heparin (moderate certainty).

1 finding from 1 review

Vitamin K antagonists vs heparin

Symptomatic VTE · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Vitamin K antagonists showed no clear difference in symptomatic VTE (DVT and PE) Treatment duration 28 ‐ 42 days compared with heparin (low certainty).

1 finding from 1 review

DOAC vs heparin

Symptomatic VTE · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

DOAC showed no clear difference in symptomatic VTE (DVT and PE) Treatment duration 28 ‐ 42 days compared with heparin (low certainty).

1 finding from 1 review

Vitamin K antagonists vs heparin

Symptomatic DVT · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Vitamin K antagonists showed no clear difference in symptomatic DVT (proximal or distal) Treatment duration 28 ‐ 42 days compared with heparin (low certainty).

1 finding from 1 review

DOAC vs heparin

Symptomatic DVT · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

DOAC showed no clear difference in symptomatic DVT (proximal or distal) Treatment duration 28 ‐ 42 days compared with heparin (low certainty).

1 finding from 1 review